<p><strong>Tandem Diabetes Care NASDAQ: TNDM</strong> 的高管在 Oppenheimer 医疗设备分析师 Suraj Kalia 主持的投资者讨论会上概述了如何通过向药房渠道转型、扩展产品组合和国际拓展，预计将在未来几年重塑公司的收入结构和利润率。</p>
<p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
<h2>药房渠道被视为短期利润驱动因素和长期销量催化剂</h2>
<p>首席财务官 Leigh Vosseller 表示，Tandem 已经开始看到进入药房渠道的早期步骤带来的财务好处。她指出，去年是公司首次进入药房，最初通过 Mobi 平台采用类似耐用医疗设备（DME）模式的报销方式。她表示，在年中，管理层看到了关于药房对患者和医生的好处的 “极大验证”，促使 Tandem 加快了计划，通过将 t:slim 供应品添加到药房渠道。</p>
<p>在第四季度，Vosseller 表示药房的销量仍然较小——不到 5% 的客户通过药房订购供应品——但仍占公司销售的约 7%。她补充说，公司记录了 “非常可观的毛利好处”，包括在第四季度创下的 58% 的最高毛利率。</p>
<p>展望未来，Vosseller 描述了从 2026 年开始的更显著的商业模式转变，预计供应品将进入药房渠道，患者如果选择 Tandem 将能够免费获得泵。她表示，在该模式下，公司预计到 2026 年，约 10% 的客户将通过药房购买供应品，全年药房销售将占约 15%。在接下来的两到三年内，她表示 Tandem 预计药房销售将上升至总销售的约 70%。</p>
<p>Vosseller 表示，这一转变预计将加速毛利率的扩张。她指出，公司预计在第四季度结束时毛利率将达到约 60%，并相信可以比没有药房机会时 “更早” 达到其长期以来的 65% 毛利率目标。她补充说，65%“不是终点”，并提到包括国际直销业务和 Mobi 增长带来的组合效益等额外杠杆。</p>
<h2>按需付费模式：PBM 覆盖、处方目录访问和定价仍在发展中</h2>
<p>Vosseller 表示，药房的进展始于药房福利管理（PBM）合同，Tandem 目前与三大主要 PBM 签订了合同，提供对约 80% 的受保人群的访问。她补充说，下一步是处方目录的安排，并且在公司的按需付费模式下，目前约三分之一的受保人群在处方目录上。</p>
<p>关于定价，Vosseller 重申，公司讨论了每月约 350 美元的净定价，但将其视为建模假设，同时 Tandem 了解合同组合、与优先和非优先安排及分级相关的回扣水平，以及可能需要的共付援助。她表示，Tandem 预计将与市场定价保持竞争力，管理层将在更多数据到来时更新投资者，了解净定价的 “稳定情况”。</p>
<p>当被问及管状设备与无管设备是否可能有不同定价时，Vosseller 表示，形态因素在短期内 “可能没有任何区别”，而报销的差异最终可能更多地与临床能力（如算法进步）相关。首席执行官 John Sheridan 补充说，像完全闭环算法这样的功能可能会创造谈判更高报销的机会，尽管他建议在接下来的几年中，两种产品的定价 “相对相似”。</p>
<h2>管理层：可负担性和可及性可能扩大泵的采用</h2>
<p>Vosseller 认为，药房渠道不仅可以推动经济效益，还可以通过降低患者的障碍来促进单位增长。她指出，可负担性是目前只有约 40% 的人使用胰岛素泵的关键原因。她表示，药房渠道使 Tandem 能够更好地影响患者的自付费用，通过共付援助以及在新模式下以零成本提供泵。相比之下，她表示，DME 渠道的患者在满足免赔额后通常需支付 800 到 1,000 美元的泵费用，如果免赔额未满足，可能还会更多。</p>
<h2>产品路线图：Mobi 无管时机、Sigi 定位和竞争因素</h2>
<p>Sheridan 表示，泵市场仍然是分段的，用户对如何佩戴和使用设备有不同的偏好。他表示，Tandem 打算提供管状和无管选项，并强调无管细分市场的增长速度快于管状细分市场，后者的年增长率为中个位数。</p>
<p>关于公司即将推出的无管产品，Sheridan 表示，Tandem 仍在按计划进行 Mobi 无管的第二季度提交，并计划在 2026 年下半年推出。他表示，竞争的基础已经从结果扩展到包括形态因素和市场准入。如果没有药房和无管产品，他表示，Tandem 面临竞争劣势，“即使我们拥有最佳算法。” 他还表示，Mobi 无管预计将是一个可延长使用的设备，配备七天的设置，提供额外的灵活性和便利性。</p>
<p>关于 Sigi，Sheridan 将其描述为下一代 Mobi 设备，预计将更小且更具差异化。他表示，公司认为 Mobi 还有 “数年的生命”，并且首先推出 Mobi 无管将使 Tandem 能够从市场反馈中学习，并将这些经验应用于 Sigi 的持续开发。</p>
<h2>国际扩展和即将到来的里程碑，包括 ADA</h2>
<p>Vosseller 表示，2025 年公司最大的费用增长是在销售和市场营销方面，这主要是由于美国的变化以及国际市场的初始投资，包括招聘国家领导和建立直接销售团队。她提到，随着公司为进一步的国家推出做准备，预计还会有额外的投资，但将这种方式描述为 “自我融资”，得益于美国药房的效率提升，而 DME 在业务中所占的比重逐渐减小。</p>
<p>Sheridan 还讨论了即将到来的催化剂和会议计划，包括预计在 6 月的美国糖尿病协会（ADA）会议上发布的产品和整合更新。他提到额外的传感器整合、关于 Mobi 的 Android 整合的信息、已提交的怀孕指示，以及对美国市场 2 型糖尿病进展的进一步讨论。</p>
<p>他补充说，Tandem 计划在第二季度将 Mobi 推向国际市场，并推出与 FreeStyle Libre 3 兼容的 t:slim。他还表示，公司正在进行 15 天 Dexcom 整合的工作，并将 Mobi 无管和与 FreeStyle Libre 3 兼容的 Mobi 视为即将推出的关键发展。</p>
<h2>关于 Tandem Diabetes Care NASDAQ: TNDM</h2>
<p>Tandem Diabetes Care, Inc NASDAQ: TNDM，总部位于加利福尼亚州圣地亚哥，是一家专注于为胰岛素依赖型糖尿病患者设计、开发和商业化创新胰岛素输送系统的医疗设备公司。公司成立于 2006 年，2011 年推出了首款产品 t:slim®胰岛素泵，并自此建立了一个包含触摸屏界面、远程软件更新和集成连续血糖监测（CGM）功能的下一代泵的产品组合。</p>
<p>公司的旗舰产品 t:slim X2®胰岛素泵，旨在与领先的 CGM 传感器配合使用，并具备根据实时血糖趋势调整基础胰岛素速率的自动胰岛素输送算法。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Tandem Diabetes Care</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Tandem Diabetes Care 吗？</h2>
<p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Tandem Diabetes Care 并不在名单上。</p>
<p>虽然 Tandem Diabetes Care 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

标普健康医疗设备 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

TNDM

2 倍做多纳斯达克生物技术 ETF - ProShares

美国医药设备 ETF - iShares

医药突破 ETF - ALPS

<p>Tandem Diabetes Care 的高管讨论了向药房渠道的战略转型，目标是在 2026 年实现 65% 的毛利率。首席财务官 Leigh Vosseller 指出，这一转型带来了早期的财务收益，预计药房销售将显著增长。公司计划在新的模式下免费提供泵，以提高可负担性和可及性。Tandem 已与主要的药房福利管理公司签订合同，覆盖 80% 的人群，并专注于具有竞争力的定价和处方目录布局，以推动胰岛素泵市场的增长</p>

<p>Executives from <strong>Tandem Diabetes Care NASDAQ: TNDM</strong> outlined how a shift toward the pharmacy channel, an expanding product portfolio, and international buildout are expected to reshape the company’s revenue mix and margin profile over the next several years during an investor discussion hosted by Oppenheimer medical device analyst Suraj Kalia.</p>
<div class="lb-trans"><p><strong>Tandem Diabetes Care NASDAQ: TNDM</strong> 的高管在 Oppenheimer 医疗设备分析师 Suraj Kalia 主持的投资者讨论会上概述了如何通过向药房渠道转型、扩展产品组合和国际拓展，预计将在未来几年重塑公司的收入结构和利润率。</p>
</div><p>Get <strong>Tandem Diabetes Care</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Tandem Diabetes Care</strong> 的提醒：</p>
</div><h2>Pharmacy channel seen as near-term margin driver and longer-term volume catalyst</h2>
<div class="lb-trans"><h2>药房渠道被视为短期利润驱动因素和长期销量催化剂</h2>
</div><p>CFO Leigh Vosseller said Tandem has already begun to see financial benefits from early steps into the pharmacy channel. She noted that last year marked the company’s first move into pharmacy, initially with the Mobi platform using a reimbursement approach that resembled the durable medical equipment (DME) model. Midway through the year, she said management saw “great validation” of assumptions about pharmacy’s benefits for both patients and physicians, prompting Tandem to move faster than planned by adding t:slim supplies to the pharmacy channel.</p>
<div class="lb-trans"><p>首席财务官 Leigh Vosseller 表示，Tandem 已经开始看到进入药房渠道的早期步骤带来的财务好处。她指出，去年是公司首次进入药房，最初通过 Mobi 平台采用类似耐用医疗设备（DME）模式的报销方式。她表示，在年中，管理层看到了关于药房对患者和医生的好处的 “极大验证”，促使 Tandem 加快了计划，通过将 t:slim 供应品添加到药房渠道。</p>
</div><p>In the fourth quarter, Vosseller said pharmacy volume remained small—less than 5% of customers ordering supplies through pharmacy—yet still represented about 7% of company sales. She added that the company recorded a “really nice gross margin benefit,” including its highest gross margin to date at 58% in Q4.</p>
<div class="lb-trans"><p>在第四季度，Vosseller 表示药房的销量仍然较小——不到 5% 的客户通过药房订购供应品——但仍占公司销售的约 7%。她补充说，公司记录了 “非常可观的毛利好处”，包括在第四季度创下的 58% 的最高毛利率。</p>
</div><p>Looking ahead, Vosseller described a more significant business model shift starting in 2026, in which supplies are expected to move into the pharmacy channel and patients would be able to obtain a pump at no cost if they choose Tandem. Under that model, she said the company expects roughly 10% of customers to be purchasing supplies via pharmacy on average across 2026, translating to pharmacy sales of about 15% for the year. Over the following two to three years, she said Tandem expects pharmacy sales to rise to about 70% of total sales.</p>
<div class="lb-trans"><p>展望未来，Vosseller 描述了从 2026 年开始的更显著的商业模式转变，预计供应品将进入药房渠道，患者如果选择 Tandem 将能够免费获得泵。她表示，在该模式下，公司预计到 2026 年，约 10% 的客户将通过药房购买供应品，全年药房销售将占约 15%。在接下来的两到三年内，她表示 Tandem 预计药房销售将上升至总销售的约 70%。</p>
</div><p>Vosseller said the shift is expected to accelerate gross margin expansion. She stated the company expects to exit this year around 60% gross margin in Q4 and believes it can reach its long-standing 65% gross margin target “much earlier” than it would have without the pharmacy opportunity. She added that 65% is “not the end,” citing additional levers including international direct business and mix benefits as Mobi grows.</p>
<div class="lb-trans"><p>Vosseller 表示，这一转变预计将加速毛利率的扩张。她指出，公司预计在第四季度结束时毛利率将达到约 60%，并相信可以比没有药房机会时 “更早” 达到其长期以来的 65% 毛利率目标。她补充说，65%“不是终点”，并提到包括国际直销业务和 Mobi 增长带来的组合效益等额外杠杆。</p>
</div><h2>Pay-as-you-go model: PBM coverage, formulary access, and pricing still developing</h2>
<div class="lb-trans"><h2>按需付费模式：PBM 覆盖、处方目录访问和定价仍在发展中</h2>
</div><p>Vosseller said pharmacy progress starts with pharmacy benefit manager (PBM) contracting, and Tandem now has contracts with the three major PBMs, providing access to about 80% of covered lives on PBM contracts. She added that the next step is formulary placement and that, under the company’s pay-as-you-go approach, about one-third of covered lives are currently on formulary.</p>
<div class="lb-trans"><p>Vosseller 表示，药房的进展始于药房福利管理（PBM）合同，Tandem 目前与三大主要 PBM 签订了合同，提供对约 80% 的受保人群的访问。她补充说，下一步是处方目录的安排，并且在公司的按需付费模式下，目前约三分之一的受保人群在处方目录上。</p>
</div><p>On pricing, Vosseller reiterated that the company has discussed net pricing of about $350 per month, but characterized it as a modeling assumption while Tandem learns more about contract mix, rebate levels tied to preferred versus non-preferred placement and tiering, and the potential need for co-pay assistance. She said Tandem expects to remain competitive with market pricing and that management will update investors as more data comes in on how net pricing “settles in.”</p>
<div class="lb-trans"><p>关于定价，Vosseller 重申，公司讨论了每月约 350 美元的净定价，但将其视为建模假设，同时 Tandem 了解合同组合、与优先和非优先安排及分级相关的回扣水平，以及可能需要的共付援助。她表示，Tandem 预计将与市场定价保持竞争力，管理层将在更多数据到来时更新投资者，了解净定价的 “稳定情况”。</p>
</div><p>Asked whether tubed versus tubeless devices could carry different pricing, Vosseller said form factor likely “doesn’t make a difference at all” in the near term, and that differentiation in reimbursement may ultimately be more tied to clinical capabilities such as algorithm advancements. CEO John Sheridan added that features like a fully closed-loop algorithm could create an opportunity to negotiate higher reimbursement, though he suggested pricing would be “relatively similar for both products” over the next couple of years.</p>
<div class="lb-trans"><p>当被问及管状设备与无管设备是否可能有不同定价时，Vosseller 表示，形态因素在短期内 “可能没有任何区别”，而报销的差异最终可能更多地与临床能力（如算法进步）相关。首席执行官 John Sheridan 补充说，像完全闭环算法这样的功能可能会创造谈判更高报销的机会，尽管他建议在接下来的几年中，两种产品的定价 “相对相似”。</p>
</div><h2>Management: affordability and access could expand pump adoption</h2>
<div class="lb-trans"><h2>管理层：可负担性和可及性可能扩大泵的采用</h2>
</div><p>Vosseller argued the pharmacy channel could drive not only economics but also unit growth by lowering barriers for patients. She pointed to affordability as a key reason why only about 40% of people use insulin pumps today. She said the pharmacy channel allows Tandem to better influence out-of-pocket costs through co-pay assistance and, under the new model, by offering the pump itself at no cost. In contrast, she said patients in the DME channel often pay an average of $800 to $1,000 for a pump after meeting a deductible, and potentially more if the deductible has not been met.</p>
<div class="lb-trans"><p>Vosseller 认为，药房渠道不仅可以推动经济效益，还可以通过降低患者的障碍来促进单位增长。她指出，可负担性是目前只有约 40% 的人使用胰岛素泵的关键原因。她表示，药房渠道使 Tandem 能够更好地影响患者的自付费用，通过共付援助以及在新模式下以零成本提供泵。相比之下，她表示，DME 渠道的患者在满足免赔额后通常需支付 800 到 1,000 美元的泵费用，如果免赔额未满足，可能还会更多。</p>
</div><h2>Product roadmap: Mobi tubeless timing, Sigi positioning, and competitive factors</h2>
<div class="lb-trans"><h2>产品路线图：Mobi 无管时机、Sigi 定位和竞争因素</h2>
</div><p>Sheridan said the pump market remains segmented, with users having different preferences for how they wear and interact with devices. He said Tandem intends to offer both tubed and tubeless options and highlighted that the tubeless segment is growing faster than the tubed segment, which he described as mid-single digit growth annually.</p>
<div class="lb-trans"><p>Sheridan 表示，泵市场仍然是分段的，用户对如何佩戴和使用设备有不同的偏好。他表示，Tandem 打算提供管状和无管选项，并强调无管细分市场的增长速度快于管状细分市场，后者的年增长率为中个位数。</p>
</div><p>On the company’s upcoming tubeless offering, Sheridan said Tandem remains on track for a Q2 submission for Mobi tubeless and a second-half 2026 launch. He said the basis of competition has broadened from outcomes to include form factor and market access. Without pharmacy and a tubeless product, he said, Tandem faced a competitive disadvantage “even though we had the best algorithm.” He also said Mobi tubeless is expected to be an extended-wear device with a seven-day set, which he described as offering additional flexibility and convenience.</p>
<div class="lb-trans"><p>关于公司即将推出的无管产品，Sheridan 表示，Tandem 仍在按计划进行 Mobi 无管的第二季度提交，并计划在 2026 年下半年推出。他表示，竞争的基础已经从结果扩展到包括形态因素和市场准入。如果没有药房和无管产品，他表示，Tandem 面临竞争劣势，“即使我们拥有最佳算法。” 他还表示，Mobi 无管预计将是一个可延长使用的设备，配备七天的设置，提供额外的灵活性和便利性。</p>
</div><p>Regarding Sigi, Sheridan described it as a next-generation Mobi device that is expected to be smaller and more differentiated. He said the company views Mobi as having “life for several years,” and that launching Mobi tubeless first will allow Tandem to learn from market feedback and apply those learnings to Sigi as development continues.</p>
<div class="lb-trans"><p>关于 Sigi，Sheridan 将其描述为下一代 Mobi 设备，预计将更小且更具差异化。他表示，公司认为 Mobi 还有 “数年的生命”，并且首先推出 Mobi 无管将使 Tandem 能够从市场反馈中学习，并将这些经验应用于 Sigi 的持续开发。</p>
</div><h2>International expansion and upcoming milestones, including ADA</h2>
<div class="lb-trans"><h2>国际扩展和即将到来的里程碑，包括 ADA</h2>
</div><p>Vosseller said the company’s largest expense increase in 2025 was in sales and marketing, driven by U.S. changes and initial investments for international markets, including hiring country leadership and building direct sales forces. She said additional investment is expected as the company prepares for further country launches, but described the approach as “self-funding,” aided by U.S. efficiencies as pharmacy grows and DME becomes a smaller part of the business.</p>
<div class="lb-trans"><p>Vosseller 表示，2025 年公司最大的费用增长是在销售和市场营销方面，这主要是由于美国的变化以及国际市场的初始投资，包括招聘国家领导和建立直接销售团队。她提到，随着公司为进一步的国家推出做准备，预计还会有额外的投资，但将这种方式描述为 “自我融资”，得益于美国药房的效率提升，而 DME 在业务中所占的比重逐渐减小。</p>
</div><p>Sheridan also discussed upcoming catalysts and conference plans, including product and integration updates anticipated at the American Diabetes Association (ADA) meeting in June. He cited additional sensor integrations, information about Android integration for Mobi, a filed pregnancy indication, and further discussion of Type 2 progress in the U.S. market.</p>
<div class="lb-trans"><p>Sheridan 还讨论了即将到来的催化剂和会议计划，包括预计在 6 月的美国糖尿病协会（ADA）会议上发布的产品和整合更新。他提到额外的传感器整合、关于 Mobi 的 Android 整合的信息、已提交的怀孕指示，以及对美国市场 2 型糖尿病进展的进一步讨论。</p>
</div><p>He added that Tandem intends to launch Mobi into international markets in Q2 and to launch t:slim with FreeStyle Libre 3. He also said the company is working on 15-day Dexcom integration during Q2 and characterized Mobi tubeless and Mobi with FreeStyle Libre 3 as key upcoming developments.</p>
<div class="lb-trans"><p>他补充说，Tandem 计划在第二季度将 Mobi 推向国际市场，并推出与 FreeStyle Libre 3 兼容的 t:slim。他还表示，公司正在进行 15 天 Dexcom 整合的工作，并将 Mobi 无管和与 FreeStyle Libre 3 兼容的 Mobi 视为即将推出的关键发展。</p>
</div><h2>About Tandem Diabetes Care NASDAQ: TNDM</h2>
<div class="lb-trans"><h2>关于 Tandem Diabetes Care NASDAQ: TNDM</h2>
</div><p>Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.</p>
<div class="lb-trans"><p>Tandem Diabetes Care, Inc NASDAQ: TNDM，总部位于加利福尼亚州圣地亚哥，是一家专注于为胰岛素依赖型糖尿病患者设计、开发和商业化创新胰岛素输送系统的医疗设备公司。公司成立于 2006 年，2011 年推出了首款产品 t:slim®胰岛素泵，并自此建立了一个包含触摸屏界面、远程软件更新和集成连续血糖监测（CGM）功能的下一代泵的产品组合。</p>
</div><p>The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.</p>
<div class="lb-trans"><p>公司的旗舰产品 t:slim X2®胰岛素泵，旨在与领先的 CGM 传感器配合使用，并具备根据实时血糖趋势调整基础胰岛素速率的自动胰岛素输送算法。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Tandem Diabetes Care</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Tandem Diabetes Care</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tandem Diabetes Care Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Tandem Diabetes Care 吗？</h2>
</div><p>Before you consider Tandem Diabetes Care, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Tandem Diabetes Care 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Tandem Diabetes Care 并不在名单上。</p>
</div><p>While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Tandem Diabetes Care 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Tandem Diabetes Care Maps Pharmacy Shift, Targets 65% Gross Margin and 2026 Mobi Tubeless Launch

Market Beat

Tandem Diabetes

Tandem Diabetes Care 制定了药房转型计划，目标是实现 65% 的毛利率，并计划在 2026 年推出 Mobi 无管设备